Julie Warner
Julie has been involved in regulatory affairs since 2003, gaining significant pre- and post-authorisation experience in disease areas ranging from oncology to cardiovascular and infectious diseases. She has a special interest in advanced therapies, orphan drugs, oncology, clinical trials and marketing authorisations.
EditorialWaltzing into change in Vienna:
The regulatory future comes into focusIt is the most wonderful time of the year – yes, that is Symposium issue time – and the Regulatory Rapporteur editorial team never want to disappoint! The TOPRA Symposium is one of the major annual events for those working in regulatory affairs, and the 2022 Symposium – hosted in ...
- Editorial
Regulatory operations: Evolution and revolution
‘Operations’ does not quite do justice to the critical role that these individuals play in the global team
- Editorial
How regulators are navigating the evolving pharmacovigilance landscape
In the area of regulatory affairs and pharmacovigilance (PV), we are constantly confronted with new laws, guidelines and other regulations
